Report - CÁNCER COLORRECTAL NUEVOS FÁRMACOS Y … · Phase III, Famitinib • Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, and it's anti-angiogenesis

Please pass captcha verification before submit form